Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesClinical/Medical PolicyCareSource Georgia Experimental Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentCareSource GeorgiaPolicy MP-AD-1354

    Experimental and Investigational Item or Service

    Customize your policy alerts

    Sign up for caresourcegeorgia Policy MP-AD-1354 alerts

    Get alerted when Policy MP-AD-1354 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs CareSource Marketplace coverage determinations for health care items and services considered experimental or investigational, including medical, surgical, diagnostic, behavioral health, drug, biologic, device, and therapeutic services.

    Policy Summary
    PayerCareSource Georgia
    PolicyExperimental and Investigational Item or Service
    Policy CodePolicy MP-AD-1354
    Change TypeMaterial update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionReview requests for experimental or investigational treatments for members under age 21 individually for medical necessity.
    SourceLink
    POLICY UPDATE CHANGES

    The policy added an individual medical-necessity review requirement for requested experimental or investigational treatments for members under age 21.

    The policy added research records to the types of evidence that may be considered during experimental or investigational review.

    The policy was revised with updated references and committee approval history.

    Not coveredExperimental or investigational items and services
    Under 21Requests reviewed individually for medical necessity
    4Net-health-outcome evidence questions

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    8Evidence sources listed for review
    01/01/2027Indiana, Ohio, and West Virginia products inactive

    Experimental and Investigational Coverage Criteria

    Experimental or investigational services

    Any health care item or service CareSource determines to be experimental or investigational is not covered.

    Non-coverage determination: The requested health care item or service is determined by CareSource to be experimental or investigational.

    Items and services determined to be experimental or investigational are not covered.

    Definitional experimental or investigational criteria

    A service is experimental or investigational when one or more of the following conditions apply.

    One or more definitional conditions

    • The item or service is not approved by the United States Food and Drug Administration (FDA) to be lawfully marketed for the proposed use.
    • The item or service is not identified in the American Hospital Formulary Service or the United States Pharmacopoeia Dispensing Information as appropriate for the proposed use.
    • The item or service is determined by the FDA to be contraindicated for the specific use.
    • Final institutional review board or similar approval for the proposed use has not been granted.
    • The item or service is the subject of an ongoing Phase 1, 2, or 3 clinical trial under FDA regulations, regardless of whether the trial is subject to FDA oversight.
    • The item or service is provided as part of a clinical research protocol or clinical trial, or in another manner intended to evaluate its safety, toxicity, or efficacy.

      Diagnostic testing for purposes of possible inclusion in a clinical trial is included.

    • The item or service is provided pursuant to informed consent that describes it as experimental or investigational, or indicates that its safety, toxicity, or efficacy is under evaluation.

    Credible research and beneficial health outcomes

    Even if the definitional criteria are not met, CareSource may determine that a service is experimental or investigational when credible research is insufficient to demonstrate a measurable and beneficial health outcome.

    All health-outcome questions must be satisfied

    • Conclusive evidence: Scientific evidence is conclusive concerning the effect of the health care item or service on health outcomes.
    • Population net benefit: Evidence demonstrates improved net health outcomes for the total population for whom the health care item or service might be proposed, with beneficial effects outweighing harmful effects.
    • Comparison with alternatives: Evidence demonstrates that the health care item or service is as beneficial for the total proposed population as any established alternatives.
    • Usual-practice outcomes:

    Members under age 21

    Requests for members under age 21 are reviewed individually for medical necessity.

    Under-21 individual review: The requested treatment is for a member under age 21 and is reviewed individually to determine whether it is medically necessary.Age under 21

    EPSDT does not require coverage of experimental or investigational treatments, services, or items; however, these requests receive an individual medical-necessity review.

    Experimental or investigational items or services are not covered. This includes, among other things, services or procedures considered investigational, cosmetic, or not medically necessary.

    Any health care item or service that CareSource determines to be experimental or investigational is not covered.

    Services or procedures considered not medically necessary are identified among the non-covered or excluded services addressed by this policy.

    Provider Review and Member Communication

    Note

    Evidence for Coverage Review

    When reviewing coverage, CareSource may consider information and evidence from one or more sources to determine whether a health care item or service is experimental or investigational. The review assesses whether the evidence is conclusive, demonstrates beneficial net health outcomes that outweigh harms, supports outcomes at least as beneficial as established alternatives, and shows benefit under usual conditions of medical practice outside clinical investigatory settings.

    • Published authoritative, peer-reviewed medical or scientific literature, including the absence of such literature
    • Evaluations by national medical associations, consensus panels, and other technology evaluation bodies
    • Documents issued by or filed with the FDA or another federal, state, or local agency authorized to approve, regulate, or investigate the item or service
    • Documents from an institutional review board or similar body
    • Provider consent documents and written research protocols
    • Medical records and research records
    • Opinions of consulting providers and other experts in the field

    Policy Scope and Context

    Experimental or investigational services covered by this policy span a broad range of care, including medical, surgical, diagnostic, psychiatric, substance use disorder, drug, biologic, device, equipment, procedure, and therapeutic services.

    Key Policy Definitions

    Definitions
    ScopeMedical, surgical, diagnostic, psychiatric, substance use disorder, and other health care services, technologies, equipment, supplies, treatments, procedures, therapies, biologics, drugs, and devices.
    Experimental or investigational statusApplies when CareSource determines that a health care item or service is not FDA-approved for the proposed use, lacks appropriate formulary or compendial support, is FDA-contraindicated, lacks required institutional review board approval, is part of a Phase 1, 2, or 3 clinical trial, is provided under a clinical research protocol, or is described in informed consent as experimental or investigational.
    CPT Category III Codes
    DefinitionCPT Category III Codes are temporary T codes assigned to emerging technologies, services, and procedures.
    PurposeThe codes are intended for data collection to substantiate more widespread usage or to provide documentation for the Food and Drug Administration approval process.
    Policy Summary
    PayerCareSource Georgia
    PolicyExperimental and Investigational Item or Service
    Policy CodePolicy MP-AD-1354
    Change TypeMaterial update
    Effective DateNovember 1, 2026
    Next Review DateN/A
    Key ActionReview requests for experimental or investigational treatments for members under age 21 individually for medical necessity.
    SourceLink
    On This Page
    Experimental and Investigational Coverage CriteriaProvider Review and Member CommunicationPolicy Scope and ContextKey Policy Definitions
    Evidence demonstrates improved net health outcomes for the total proposed population under the usual conditions of medical practice outside clinical investigatory settings.
    Documentation Required

    Notify Members of Potential Financial Responsibility

    Providers are encouraged to notify members in advance when the member may be financially responsible for the cost of non-covered or excluded services. Members have the right to refuse or participate in experimental or investigational items or services.

    • Discuss potential financial responsibility before providing non-covered or excluded services.
    Denial Risk

    Experimental or Investigational Determination

    Any health care item or service that CareSource determines to be experimental or investigational is not covered. This includes items or services that meet the applicable regulatory, clinical-trial, research-protocol, informed-consent, or evidence criteria.

    • Requested treatments for members under age 21 are reviewed individually to determine whether they are medically necessary; EPSDT does not require coverage of experimental or investigational treatments, services, or items.
    Denial Risk

    Regulatory, Trial, and Consent Triggers

    CareSource may determine that an item or service is experimental or investigational when regulatory, trial, research, or consent-based conditions apply. These conditions include lack of FDA approval for the proposed use, lack of recognized formulary or compendia support, FDA contraindication, pending institutional review board approval, qualifying Phase 1–3 clinical-trial participation, clinical research evaluation, or informed consent describing the item or service as experimental or investigational or under evaluation.

    • Diagnostic testing performed for possible inclusion in a qualifying Phase 1, 2, or 3 clinical trial is included.
    • Devices approved under the FDA Humanitarian Use Device exemption are not considered experimental or investigational.
    • Drugs used in Phase 4 trials may be covered when they are part of the formulary.
    Denial Risk

    Insufficient Credible Evidence

    An item or service that does not meet the specific experimental or investigational criteria in Section C may still be determined to be experimental or investigational when credible research does not soundly demonstrate a measurable and beneficial health outcome.

    • CareSource evaluates whether the scientific evidence is conclusive concerning health outcomes.
    • The evidence must demonstrate beneficial net health outcomes for the relevant population, with benefits outweighing harms.
    • The item or service must be at least as beneficial for the relevant population as established alternatives.
    • The item or service must improve net health outcomes under usual conditions of medical practice outside clinical investigatory settings.
    Humanitarian Use Device exemption
    Policy treatmentDevices that are FDA approved under the Humanitarian Use Device exemption are not considered experimental or investigational.
    Phase 4 trial drugs
    Coverage conditionDrugs used in Phase 4 trials may be covered if they are part of the formulary.